Merrill Lynch maintains UCB at buy

UCB was maintained by Merrill Lynch analyst Erika Whittaker at a buy rating with a price objective of €48 following Tuesday's phase III data release on Cimzia for Crohn's disease, which showed strong efficacy and no unexpected safety issues. Merrill Lynch believes the drug is the company's next growth driver with launch expected in early 2007. Shares of the Brussels, Belgium, pharmaceutical company were down €3.2958, or 6.16%, at €50.2042 on volume of 5,900 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.